PB2145: REAL-WORLD THERAPY LINES IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) – A POPULATION-BASED ANALYSIS

por Duell, J., Weinand, S., Kaworski, T., Schubert, T.
Publicado 2022

Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL

por Duell, J, Dittrich, M, Bedke, T, Mueller, T, Eisele, F, Rosenwald, A, Rasche, L, Hartmann, E, Dandekar, T, Einsele, H, Topp, M S
Publicado 2017

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia

por Topp, M S, Stelljes, M, Zugmaier, G, Barnette, P, Heffner, L T, Trippett, T, Duell, J, Bargou, R C, Holland, C, Benjamin, J E, Klinger, M, Litzow, M R
Publicado 2018

Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes

por Steinhardt, M. J., Wiercinska, E., Pham, M., Grigoleit, G. U., Mazzoni, A., Da-Via, M., Zhou, X., Meckel, K., Nickel, K., Duell, J., Krummenast, F. C., Kraus, S., Hopkinson, C., Weissbrich, B., Müllges, W., Stoll, G., Kortüm, K. M., Einsele, H., Bonig, H., Rasche, L.
Publicado 2020